54
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      A research agenda for ageing in China in the 21st century (2nd edition): Focusing on basic and translational research, long-term care, policy and social networks

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Highlights

          • Covered broad fields of ageing in China: In addition to an update of the statistics of ageing and disease burden, we include basic and translational research, long-term care, policy and social networks;

          • Provided more detailed numerical updates of the ageing challenges in China (4 Figures, plus one summary figure of Fig. 5).

          • Some new features of the aging-related challenges which were not mentioned in the 1st edition, are included, e.g., oral ageing and STDs in the elderly in China; and

          • A new and independent section on immune ageing, covering viral hepatitis, tuberculosis, AIDS, Influenza and Pneumonia in the Chinese elderly. We also mentioned the COVID-19-induced death in the Chinese elderly.

          Abstract

          One of the key issues facing public healthcare is the global trend of an increasingly ageing society which continues to present policy makers and caregivers with formidable healthcare and socio-economic challenges. Ageing is the primary contributor to a broad spectrum of chronic disorders all associated with a lower quality of life in the elderly. In 2019, the Chinese population constituted 18 % of the world population, with 164.5 million Chinese citizens aged 65 and above (65+), and 26 million aged 80 or above (80+). China has become an ageing society, and as it continues to age it will continue to exacerbate the burden borne by current family and public healthcare systems. Major healthcare challenges involved with caring for the elderly in China include the management of chronic non-communicable diseases (CNCDs), physical frailty, neurodegenerative diseases, cardiovascular diseases, with emerging challenges such as providing sufficient dental care, combating the rising prevalence of sexually transmitted diseases among nursing home communities, providing support for increased incidences of immune diseases, and the growing necessity to provide palliative care for the elderly. At the governmental level, it is necessary to make long-term strategic plans to respond to the pressures of an ageing society, especially to establish a nationwide, affordable, annual health check system to facilitate early diagnosis and provide access to affordable treatments. China has begun work on several activities to address these issues including the recent completion of the of the Ten-year Health-Care Reform project, the implementation of the Healthy China 2030 Action Plan, and the opening of the National Clinical Research Center for Geriatric Disorders. There are also societal challenges, namely the shift from an extended family system in which the younger provide home care for their elderly family members, to the current trend in which young people are increasingly migrating towards major cities for work, increasing reliance on nursing homes to compensate, especially following the outcomes of the ‘one child policy’ and the ‘empty-nest elderly’ phenomenon. At the individual level, it is important to provide avenues for people to seek and improve their own knowledge of health and disease, to encourage them to seek medical check-ups to prevent/manage illness, and to find ways to promote modifiable health-related behaviors (social activity, exercise, healthy diets, reasonable diet supplements) to enable healthier, happier, longer, and more productive lives in the elderly. Finally, at the technological or treatment level, there is a focus on modern technologies to counteract the negative effects of ageing. Researchers are striving to produce drugs that can mimic the effects of ‘exercising more, eating less’, while other anti-ageing molecules from molecular gerontologists could help to improve ‘healthspan’ in the elderly. Machine learning, ‘Big Data’, and other novel technologies can also be used to monitor disease patterns at the population level and may be used to inform policy design in the future. Collectively, synergies across disciplines on policies, geriatric care, drug development, personal awareness, the use of big data, machine learning and personalized medicine will transform China into a country that enables the most for its elderly, maximizing and celebrating their longevity in the coming decades. This is the 2nd edition of the review paper (Fang EF et al., Ageing Re. Rev. 2015).

          Related collections

          Most cited references163

          • Record: found
          • Abstract: found
          • Article: not found

          Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

          Summary Background In December, 2019, a pneumonia associated with the 2019 novel coronavirus (2019-nCoV) emerged in Wuhan, China. We aimed to further clarify the epidemiological and clinical characteristics of 2019-nCoV pneumonia. Methods In this retrospective, single-centre study, we included all confirmed cases of 2019-nCoV in Wuhan Jinyintan Hospital from Jan 1 to Jan 20, 2020. Cases were confirmed by real-time RT-PCR and were analysed for epidemiological, demographic, clinical, and radiological features and laboratory data. Outcomes were followed up until Jan 25, 2020. Findings Of the 99 patients with 2019-nCoV pneumonia, 49 (49%) had a history of exposure to the Huanan seafood market. The average age of the patients was 55·5 years (SD 13·1), including 67 men and 32 women. 2019-nCoV was detected in all patients by real-time RT-PCR. 50 (51%) patients had chronic diseases. Patients had clinical manifestations of fever (82 [83%] patients), cough (81 [82%] patients), shortness of breath (31 [31%] patients), muscle ache (11 [11%] patients), confusion (nine [9%] patients), headache (eight [8%] patients), sore throat (five [5%] patients), rhinorrhoea (four [4%] patients), chest pain (two [2%] patients), diarrhoea (two [2%] patients), and nausea and vomiting (one [1%] patient). According to imaging examination, 74 (75%) patients showed bilateral pneumonia, 14 (14%) patients showed multiple mottling and ground-glass opacity, and one (1%) patient had pneumothorax. 17 (17%) patients developed acute respiratory distress syndrome and, among them, 11 (11%) patients worsened in a short period of time and died of multiple organ failure. Interpretation The 2019-nCoV infection was of clustering onset, is more likely to affect older males with comorbidities, and can result in severe and even fatal respiratory diseases such as acute respiratory distress syndrome. In general, characteristics of patients who died were in line with the MuLBSTA score, an early warning model for predicting mortality in viral pneumonia. Further investigation is needed to explore the applicability of the MuLBSTA score in predicting the risk of mortality in 2019-nCoV infection. Funding National Key R&D Program of China.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            From discoveries in ageing research to therapeutics for healthy ageing

            For several decades, understanding ageing and the processes that limit lifespan have challenged biologists. Thirty years ago, the biology of ageing gained unprecedented scientific credibility through the identification of gene variants that extend the lifespan of multicellular model organisms. Here we summarize the milestones that mark this scientific triumph, discuss different ageing pathways and processes, and suggest that ageing research is entering a new era that has unique medical, commercial and societal implications. We argue that this era marks an inflection point, not only in ageing research but also for all biological research that affects the human healthspan.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study

              Background Cellular senescence is a key mechanism that drives age-related diseases, but has yet to be targeted therapeutically in humans. Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal cellular senescence-associated disease. Selectively ablating senescent cells using dasatinib plus quercetin (DQ) alleviates IPF-related dysfunction in bleomycin-administered mice. Methods A two-center, open-label study of intermittent DQ (D:100 mg/day, Q:1250 mg/day, three-days/week over three-weeks) was conducted in participants with IPF (n = 14) to evaluate feasibility of implementing a senolytic intervention. The primary endpoints were retention rates and completion rates for planned clinical assessments. Secondary endpoints were safety and change in functional and reported health measures. Associations with the senescence-associated secretory phenotype (SASP) were explored. Findings Fourteen patients with stable IPF were recruited. The retention rate was 100% with no DQ discontinuation; planned clinical assessments were complete in 13/14 participants. One serious adverse event was reported. Non-serious events were primarily mild-moderate, with respiratory symptoms (n = 16 total events), skin irritation/bruising (n = 14), and gastrointestinal discomfort (n = 12) being most frequent. Physical function evaluated as 6-min walk distance, 4-m gait speed, and chair-stands time was significantly and clinically-meaningfully improved (p < .05). Pulmonary function, clinical chemistries, frailty index (FI-LAB), and reported health were unchanged. DQ effects on circulat.ing SASP factors were inconclusive, but correlations were observed between change in function and change in SASP-related matrix-remodeling proteins, microRNAs, and pro-inflammatory cytokines (23/48 markers r ≥ 0.50). Interpretation Our first-in-humans open-label pilot supports study feasibility and provides initial evidence that senolytics may alleviate physical dysfunction in IPF, warranting evaluation of DQ in larger randomized controlled trials for senescence-related diseases. ClinicalTrials.gov identifier: NCT02874989 (posted 2016–2018).
                Bookmark

                Author and article information

                Journal
                Ageing Res Rev
                Ageing Res. Rev
                Ageing Research Reviews
                Elsevier B.V.
                1568-1637
                1872-9649
                21 September 2020
                21 September 2020
                : 101174
                Affiliations
                [a ]Department of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, 1478 Lørenskog, Norway
                [b ]The Norwegian Centre on Healthy Ageing (NO-Age), Oslo, Norway
                [c ]Department of Hypertension and Vascular Disease, The First Affiliated Hospital, Sun Yat-Sen University, 510080, Guangzhou, China
                [d ]Institute of Geriatric Immunology, School of Medicine, Jinan University, 510632, Guangzhou, China
                [e ]Department of Geriatrics, The First Affiliated Hospital, Zhengzhou University, 450052, Zhengzhou, China
                [f ]Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
                [g ]School of Applied Social Sciences, Durham University, United Kingdom
                [h ]Global Health Research Center, Duke Kunshan University, 215316, Kunshan, China
                [i ]Duke Global Health Institute, Duke University, Durham, 27710, North Carolina, USA
                [j ]Department of Endodontics, Shanghai Stomatological Hospital, Fudan University, China
                [k ]Oral Biomedical Engineering Laboratory, Shanghai Stomatological Hospital, Fudan University, China
                [l ]Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-sen University, 510275, Guangzhou, China
                [m ]Sun Yat-sen Global Health Institute, Institute of State Governance, Sun Yat-sen University, 510275, Guangzhou, China
                [n ]School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, China
                [o ]Kirby Institute, University of New South Wales, Sydney, Australia
                [p ]Pinetree Care Group, 515 Tower A, Guomen Plaza, Chaoyang District, 100028, Beijing, China
                [q ]Department of Sociology and Work Science, University of Gothenburg, SE-405 30, Gothenburg, Sweden
                [r ]School of Public Affairs, Zhejiang University, Hangzhou, 310058, Zhejiang, China
                [s ]BGI-Shenzhen, Beishan Industrial Zone, 518083, Shenzhen, China
                [t ]China National GeneBank, BGI-Shenzhen, 518120, Shenzhen, China
                [u ]Department of Public Health, Erasmus University Medical Centre, Rotterdam, the Netherlands
                [v ]Aladdin Healthcare Technologies Ltd., 24-26 Baltic Street West, London EC1Y OUR, UK; and Ocean’s Smart Ltd., 11th Floor, Building 15, Singapore Science & Technology Park, Qiantang New District, Hangzhou, Zhejiang Province, China
                [w ]Cardiovascular Research Centre, Royal Brompton Hospital, London, SW3 6NP, UK; and National Heart and Lung Institute, Imperial College London, London, SW7 2AZ, United Kingdom
                [x ]Mindrank AI, Hangzhou, Zhejiang Province, China
                [y ]Department of Biochemistry and Molecular Biology, The Institute of Basic Medical Sciences, The Chinese Academy of Medical Sciences (CAMS)& Peking Union Medical University (PUMC), 5 Dondan Santiao Road, Beijing, 100730, China
                [z ]Department of Geriatrics, Peking Union Medical College Hospital, Beijing, 100730, China
                [A ]State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao
                [B ]Department of Toxicology, Zhejiang University School of Public Health, Hangzhou, 310058, Zhejiang, China
                [C ]The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, 322000, Zhejiang, China
                [D ]Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
                [E ]Laboratory of Medical Genetics, Central South University, Changsha, China
                [F ]National Clinical Research Center for Geriatric Diseases, Central South University, Changsha, China
                [G ]Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, China
                [H ]School of Public Health, Fudan University, 200032, Shanghai, China
                [I ]Key Laboratory of Public Health Safety of Ministry of Education, Fudan University, 200032, Shanghai, China
                [J ]Key Laboratory of Health Technology Assessment of Ministry of Health, Fudan University, 200032, Shanghai, China
                [K ]Division of Geriatric Medicine and Gerontology, Johns Hopkins University School of Medicine, 5505 Hopkins Bayview Circle, Baltimore, MD 21224, USA
                [L ]Research Center on Ageing, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing Key Laboratory of Protein Posttranslational Modifications and Cell Function, Beijing, China
                [M ]Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China
                Author notes
                [* ]Corresponding author at: Department of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, 1478 Lørenskog, Norway.
                Article
                S1568-1637(20)30309-3 101174
                10.1016/j.arr.2020.101174
                7505078
                32971255
                8a711882-61e5-47e3-a8d7-6ac689ea57da
                © 2020 Elsevier B.V. All rights reserved.

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                : 24 March 2020
                : 13 August 2020
                : 3 September 2020
                Categories
                Review

                ageing policy,sexually transmitted diseases,inflammageing,dementia,oral ageing,square dancing

                Comments

                Comment on this article